MAPK signaling regulates the efficacy of chemoimmunotherapy

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2022-04-27 DOI:10.1080/23723556.2022.2054652

F. Ghiringhelli

引用次数: 0

Abstract

ABSTRACT Resistance to chemoimmunotherapy is a major issue for cancer care. We recently unravelled the role of mitogen-activated protein kinase (MAPK) to limit the antitumor efficacy of such combination. Inhibitor of MAPK pathway using mitogen-activated protein kinase (MEK) inhibitor in combination with chemotherapy triggers mitophagy of cancer cells, which induces the release of mitochondrial DNA that interact with Toll Like receptor 9 (TLR9) to promote the production of the chemokine CXCL10. CXCL10 could then turn cold tumor into hot tumor, thus leading to improve efficacy of chemoimmunotherapy.

查看原文本刊更多论文

MAPK信号调节化学免疫治疗的疗效

化疗免疫治疗的耐药是癌症治疗的一个主要问题。我们最近揭示了丝裂原活化蛋白激酶(MAPK)的作用，以限制这种组合的抗肿瘤疗效。使用丝裂原活化蛋白激酶(MEK)抑制剂联合化疗抑制MAPK通路，触发癌细胞的有丝分裂，诱导线粒体DNA的释放，与Toll样受体9 (TLR9)相互作用，促进趋化因子CXCL10的产生。CXCL10可以将冷肿瘤转化为热肿瘤，从而提高化学免疫治疗的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.